Methylprednisolone worsening neuropathic pain in non-traumatic thoracic myelopathy

Y-T Wu1, S-L Chiang, M-H Lai

  • 1Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Neihu District, Taipei, Taiwan.

Insights

Methylprednisolone (MP) may not improve outcomes for spontaneous spinal epidural hematoma (SSEH). High-dose MP treatment in this case was followed by severe neuropathic pain, suggesting potential steroid misuse.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Methylprednisolone (MP) is a common treatment for spinal cord injury, but its efficacy and side effects are debated.
  • Spontaneous spinal epidural hematoma (SSEH) typically requires surgical decompression for good neurological recovery.

Observation:

  • A patient with SSEH received high-dose MP 16 hours after symptom onset, followed by surgery.
  • While motor function recovered well, the patient developed severe, intractable neuropathic pain 5 weeks post-surgery.

Findings:

  • This case suggests that high-dose MP may not be beneficial and could potentially contribute to adverse outcomes like intractable pain in SSEH.
  • The development of severe neuropathic pain was speculated to be linked to the timing and dosage of steroid administration.

Implications:

  • Rethinking the use of MP in non-traumatic spinal myelopathy cases like SSEH is warranted.
  • Further research is needed to understand the risks and benefits of MP in specific spinal cord injury contexts.
  • Clinical guidelines for MP use in SSEH may need revision to prevent potential complications.